Bensen Daniel 4

What Happened
Daniel Bensen, Chief Discovery Officer of Tyra Biosciences (TYRA), sold a total of 8,000 shares in two open‑market transactions on February 12, 2026, generating combined proceeds of approximately $262,965. The sales broke down as 2,128 shares at a weighted average price of $31.50 (≈ $67,036) and 5,872 shares at a weighted average price of $33.37 (≈ $195,929). These were sales (not purchases), which are commonly routine disposals rather than a direct bullish signal.

Key Details

• Transaction date: February 12, 2026; Form 4 filed February 13, 2026 (appears timely).
• Shares sold: 2,128 @ $31.50 (weighted avg; actual prices $31.02–$31.75) and 5,872 @ $33.37 (weighted avg; actual prices $32.98–$33.85).
• Total shares sold: 8,000; total proceeds: ~$262,965.
• Shares owned after transaction: Not specified in the provided filing excerpt.
• Footnotes: Sales were effected pursuant to a Rule 10b5‑1 trading plan adopted November 5, 2024. Exact per‑trade price breakdowns are available from the issuer on request.
• Transaction code: S = Sale.

Context
Sales executed under a pre‑arranged 10b5‑1 plan are scheduled trades intended to avoid timing based on inside information; they are common among executives and often indicate routine portfolio management rather than a view on the company’s prospects. For retail investors, purchases typically carry more direct informational value than routine insider sales.